Biogen Idec (NASDAQ:BIIB)

How Biotech and Big Pharma Have Upside Heading Into Earnings

Biotech and many of the so-called Big Pharma have been duds in 2019. Despite many FDA approvals and some powerful mergers and royalty deals, the political pressure around drug pricing ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Agilent, Alphabet, Altria, Amazon, Boeing, Caterpillar, Chipotle, E*Trade, Gap, Snap, Twitter and More

Stocks were indicated to open marginally higher on Friday as earnings season is so far proving to be not as bad as many investors had modeled in for the third ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Abbott Labs, CSX, IBM, Netflix, Occidental, Whiting, Amgen, Gilead, Merck, Pfizer and More

Stocks were indicated to open marginally higher on Thursday as the world appears to have better hopes for a Brexit framework out of Europe. Investors are having to grapple with ...
Read Full Story »

Short Sellers Hike Bets in Major Biotechs

The short interest data are out for the most recent settlement date, September 30. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big ...
Read Full Story »

Major Biotechs Scare Off Short Sellers

The short interest data are out for the most recent settlement date, September 13. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big ...
Read Full Story »

Major Biotechs Scare Off Short Sellers

The short interest data are out for the most recent settlement date, August 30. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big ...
Read Full Story »

Short Sellers Hike Their Bets in Biotech

The short interest data are out for the most recent settlement date, August 15. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big ...
Read Full Story »

Dividend Investors Have Reasons to Look to Big Biotech Over Big Pharma Ahead

Over the past three decades, the unlimited investing potential of biotechnology was all about growth. Companies could grow from nothing to see untold billions of dollars selling cures and treatments ...
Read Full Story »

Short Sellers Make a Move on Big Biotechs

The short interest data are out for the most recent settlement date, July 31. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big ...
Read Full Story »

Oil & Gas, Apparel, Pharma Vying for S&P 500’s Worst Group of 2019

The stock market has experienced yet another 5% correction after hitting all-time highs just in July. What really stands out for 2019, particularly if you just followed the emotions of ...
Read Full Story »

Major Biotechs See Rising Tide in Short Interest

The short interest data are out for the most recent settlement date, July 15. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big ...
Read Full Story »

Why Biogen’s Q2 Was So Great

When Biogen Inc. (NASDAQ: BIIB) released its second-quarter financial results before the markets opened on Tuesday, the biotech giant said that it had $9.15 in earnings per share (EPS) and ...
Read Full Story »

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the most recent settlement date, June 28. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big ...
Read Full Story »

Many Top Pharma & Biotechs Rise as Drug Price Disclosure Thrown Out

While the public wants more pharmaceuticals and biotech advancements to treat the endless number of ailments or to extend their lives, there is a simultaneous push to make drugs more ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Aerojet Rocketdyne, Apple, Baidu, Biogen, Chesapeake Energy, Chipotle, McDonald’s, Nike, Procter & Gamble, Walgreens and More

It seems impossible to fathom, but this is the last day of the second quarter in 2019. The bull market is well into its 10th year, and the major indexes ...
Read Full Story »